Compare AbCellera Biologics Inc (ABCL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs TransMedics Group Inc — how do they compare? AbCellera Biologics Inc trades at $7.16 (market cap $2.35B), while TransMedics Group Inc trades at $70.4 (market cap $2.46B). The key difference: AbCellera Biologics Inc and TransMedics Group Inc are close in size by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | TMDX | |
|---|---|---|
Market Cap | $2.35B | $2.46B |
Sector | Health | Technology |
52-Week High | $8.12 | $150.42 |
52-Week Low | $2.78 | $61.99 |
Enterprise Value | $1.99B | $2.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
TMDX trades at $71.23, up 3.44% on the day, but technical indicators signal a bearish trend. The company reported strong profitability with a 27.04% net income margin and 45.22% ROE for 2025, though Q1 2026 earnings missed expectations. Recent strategic investments in European organ logistics aim to expand its competitive moat, but margin pressure from expansion costs is a key concern noted by analysts (Zacks Investment Research, 2026-07-07).
The investment outlook is mixed: strong analyst consensus (75% buy ratings) and a $108.71 price target suggest significant upside, but near-term execution risks and bearish technicals warrant caution. Long-term growth drivers in transplant logistics are compelling, yet investors must weigh expansion costs against the potential for market share gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
